MedTrace Logo

Purified Inactivated Japanese Encephalitis Vaccine

NCT04223037 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1050

Last updated 2022-03-09

No results posted yet for this study

Summary

This study evaluates the immunogenicity and safety of a purified inactivated JE vaccine compared to a commercialized JE vaccine. In this phase III, randomized, blind trial, infants at 6-23 months of age were randomly assigned to three groups to receive experimental vaccine or control vaccine with two different vaccination schedule respectively.

Conditions

  • Japanese Encephalitis Virus Disease

Interventions

BIOLOGICAL

Japanese Encephalitis Vaccine produced by IMBCAMS

Dosage form: 0.5mL/vial

BIOLOGICAL

Japanese Encephalitis Vaccine produced by Liaoning Chenda

Dosage form: 0.5mL/vial

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Shaohong Yan · Disease prevention and control center of Inner Mongolia autonomous region

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
23 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2018-03-07
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04223037 on ClinicalTrials.gov